trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['breast', 'agent', 't-dxd']
clear talk of the anti-her2 future directions by #shanumodi at #esmo22 t-dxd represents the 1st approved adc for #her2low breast cancer but new adcs (single-agent &amp;combo) are under investigation novel predictive markers are needed to personalize treatments 
Scientific Communication Manager | Passionate about molecular oncology, clinical and translational research | Photo and music enthusiast | Tweets are mine